Revlimid revenue cliff
Generic Revlimid contribution expected to become immaterial from Q3 FY26, creating a revenue gap that new launches may not fully offset in the near term.
high · management_commentaryCipla Ltd — Q2 FY26
Cipla delivered an all-time high quarterly revenue of INR 7,589 crore (+8% YoY) with a robust EBITDA margin of 25%, driven by broad-based growth across One India, US Generics, O...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Execution risk on US pipeline launches
Delays in FDA approvals for key respiratory and peptide assets could impact the $1B US revenue target.
medium · analyst_questionIndia branded business growth slowdown
India branded business grew only 7% YoY, below the market, due to weak acute season and team restructuring.
medium · analyst_questionTirzepatide exclusivity and competition
Potential competition from semaglutide generics and uncertainty over exclusivity terms with Lilly could limit tirzepatide upside.
medium · analyst_question